Akebia Therapeutics (AKBA) Misses Q4 EPS by 38c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. CRWD
2. AAPL
3. PLTR
4. LITE
5. REGN
6. ABBV
7. MRVL
8. CL
9. CHKP
10. LYB

Go back to Akebia Therapeutics (AKBA) Misses Q4 EPS by 38c

Akebia Announces Fourth Quarter and Full-Year 2015 Financial Results

March 14, 2016 4:05 PM EDT

-Company to Host Conference Call at 4:30 PM Eastern Time-

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients through the biology of hypoxia-inducible factor (HIF), today announced financial results for the fourth quarter and full year ended December 31, 2015.

During 2015, we successfully executed all of our clinical and corporate objectives and we are well-positioned to build on this momentum in 2016, stated John P. Butler, President and Chief Executive Officer of Akebia. We have continued to demonstrate the therapeutic potential... More